Beacon Pharmaceuticals (DHA:BEACONPHAR) Debt-to-EBITDA

: 3.49 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Beacon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was BDT7,657 Mil. Beacon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was BDT1,960 Mil. Beacon Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was BDT2,753 Mil. Beacon Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 3.49.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Beacon Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

DHA:BEACONPHAR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.42 Med: 4.49 Max: 6.46
Current: 6.46

During the past 8 years, the highest Debt-to-EBITDA Ratio of Beacon Pharmaceuticals was 6.46. The lowest was 1.42. And the median was 4.49.

DHA:BEACONPHAR's Debt-to-EBITDA is ranked worse than
85.71% of 658 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs DHA:BEACONPHAR: 6.46

Beacon Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Beacon Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beacon Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

Get a 7-Day Free Trial

4.88

2.58

1.42

1.85

4.49

Beacon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															2.06	-119.99	10.24	3.03	3.49

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beacon Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beacon Pharmaceuticals Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Beacon Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Beacon Pharmaceuticals's Debt-to-EBITDA falls into.

Beacon Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Beacon Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6682.828	+	772.479)	/	1658.91
	=	4.49

Beacon Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(7656.777	+	1960.198)	/	2753.128
	=	3.49

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Beacon Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Beacon Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beacon Pharmaceuticals PLC (DHA:BEACONPHAR) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

9/B/2, Toyenbee Circular Road, Motijheel C/A, Beacon Business Centre, Dhaka, BGD, 1223

Website

https://www.beaconpharma.com.bd

Beacon Pharmaceuticals PLC manufactures and markets pharmaceutical products. Its products are used in various therapeutic areas, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, and muscle relaxants. The company exports its products to Europe, America, Australia, Africa, and Asia. The company's products can be segmented as General, Chronic Care, Oncology, and Biotech products.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Headlines

No Headlines